Daily Archives: April 20, 2024

To capture the hearts and minds of consumers through a shared love for ftbol, Lowes is delivering a hat trick for ftbol fans. Lowes is partnering with the best ftbol player in the world, Lionel Messi, Major League Soccer Club Inter Miami CF and the upcoming CONMEBOL Copa Amrica 2024 USA.

Through a multiyear agreement, Messi also becomes a member of Lowes Home Team, making him the first ftbol player to join the lineup of top NFL and NBA athletes who have helped improve communities around the country since 2020.

Lionel Messi is the GOAT of the assist, said Jen Wilson, Lowe's senior vice president of enterprise brand and marketing. Partnering with him is the perfect reflection of Lowes shared passion for assisting our customers, whether for their business or home.

To kick off his first season, Lowes and Messi will assist Lowes loyalty customers with extra perks. Starting today, all loyalty members will receive 100 points to get them closer to their next reward through Lowes new loyalty program for homeowners, MyLowes Rewards, and Lowes MVPs Pro Rewards for Pros. MyLowes Rewards members must claim points on their account dashboard by May 18.*

Ftbol, much like home improvement, is all about teamwork and the assistance between people, Messi said. I am happy to partner with Lowes, a brand that understands the importance of collaboration and helping people succeed.

Inter Miami has quickly become the focal point of ftbol in North America. The new partnership between Lowes and Inter Miami will drive engagement with ftbol fans with signage and in-stadium activations, community programming, ticket hospitality, player appearances at Lowes locations throughout the Miami market and more.

Inter Miami has worked towards becoming a global reference point of ftbol, so that when people think of ftbol, they think of Inter Miami, said Inter Miami CF Chief Business Officer, Xavier Asensi. Our partnership with Lowes is another proof point of attaining this ambition. We are excited to partner with Lowes, an organization that matches our goal to continue to set the benchmark for the sport and deliver for our ftbol family.

Lowes will also team up with CONMEBOL Copa Amrica 2024 USA, which returns to the United States with Argentina defending its crown beginning June 20. Lowes has a series of exciting initiatives to celebrate the magic of Messi:

To celebrate ftbols rich culture and community, we wanted to partner with an athlete and ftbol affiliations that resonate deeply with our customers, said Gerardo Soto, Lowe's vice president of brand marketing and sports partnerships. These new partnerships provide an opportunity to build trust and credibility with a broader customer base through the athletes and sporting events that matter to them.

The partnerships add to Lowes existing collaboration with Charlotte FC, Lowes hometown Major League Soccer club. As the Official Home Improvement Partner of Inter Miami CF and CONMEBOL Copa Amrica 2024 USA, Lowes will enhance the ftbol experience for fans while bringing them closer to the excitement of Messi's gameplay.

For more information about Lowes partnerships and upcoming ftbol initiatives, visit Lowes.com/hometeam.

* Loyalty Programs subject to Terms & Conditions. Visit Lowes.com/Terms for details. Subject to change.

**All Bonus Points will expire on December 31, 2024, unless extended by Lowes. Reward Center items may vary. Visit Lowes.com/terms for full details.

See the original post:

Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Ftbol ... - Inter Miami CF

A novel treatment strategy for cystic fibrosis (CF) thats based on a cellular structure called the porosome showed promise in cell and animal models of CF caused by the common F508del mutation.

In the cell model, this approach was more potent than tezacaftor and ivacaftor, which are CFTR modulators used in approved CF therapies,according to data presented by Porosome Therapeutics, the company developing the approach.

Findings were showcased at the April summit of the American Physiological Society in Long Beach, California, in the poster Cystic fibrosis rescued using a reprogrammed porosome secretory machinery.

These new results mark a major breakthrough in our efforts to find a path to a cure, not only for CF but for a wide range of debilitating diseases and chronic conditions, Guillermo Marmol, president and CEO of Porosome Therapeutics, said in a press release sent to Cystic Fibrosis News Today. Marmol noted that the company is focused on bringing this approach into clinical testing in people.

We are diligently conducting further studies to comprehensively assess the safety, stability, and optimal dosage of this approach, said Bhanu P. Jena, PhD, the companys founder and chairman.

CF is caused by mutations in the gene that encodes the CFTR protein. This protein normally helps regulate the flow of chloride ions across the cell membrane. Problems in the workings of CFTR lead to the production of abnormally thick, sticky mucus, which builds in organs to drive most disease symptoms.

The porosome is a complex of dozens of proteins, including CFTR, that work together to regulate the movement of molecules out of cells. The therapeutic approach described here basically involves taking porosomes from cells with healthy CFTR protein and transplanting them into CF cells.

Reconstitution of functional porosomes having normal CFTR, therefore holds great promise in treating CF with all different types of CFTR mutations, the researchers wrote.

Researchers first tested this approach in a cell model of CF caused by the most common CF-causing mutation, F508del. As in CF patients, cells in this particular model characteristically secrete lower-than-normal levels of certain mucus proteins, including MUC5B and MUC5AC.

The porosome-based treatment increased secretion of these mucus proteins from CF cells. Notably, the porosome therapy had a significantly more potent effect on mucus protein secretion compared to tezacaftor and ivacaftor, which in CFTR modulators work by boosting the functionality of the faulty CFTR protein.

These findings indicate that porosome-reconstitution therapy is a powerful approach, the researchers wrote.

Scientists next tested the porosome-based treatment in a mouse model of CF caused by the F508del mutation.

In these experiments, they evaluated the effect of the treatment on CFTR function using a well-established measure called the nasal potential difference, which records the small electrical charge that occurs in the airway lining inside the nose. Results indicated that the porosome therapy normalized CFTR function.

Porosomes obtained from functional [healthy] human bronchial epithelial cells were used to treat the nasal passages of CF-affected mice. Remarkably, within 24 hours of treatment, this reconstitution of the porosome rescued chloride secretion in the nasal passage, Jena said.

See the rest here:

Porosome treatment targeting CFTR shows promise in CF models - Cystic Fibrosis News Today

At 31, I still love basketball, and Ive been a New York Knicks fan for 25 years.

For the first 21 years of my fandom, the franchise was a model of instability and getting in its own way. I try to approach my health in the exact opposite manner, which is to say that I do so with similar determination and stability that the Knicks have had for the last four years.

As an adult with cystic fibrosis (CF), I find that maintaining stability with my health is often more of a mental battle than a physical one. Overcoming the anxiety and fear that come with living with this disease isnt easy.

In January, I was hospitalized with pneumonia for a week for the second time in three months. Having pneumonia isnt new to me, as Ive battled it at least once a year for the past three years. However, because it reared its ugly head again so quickly, Ive been on high alert for any sudden changes in my body.

Whether its coughing more one day than on the previous day or monitoring my stomach when its misbehaving (I had a sepsis infection in my digestive system in 2019), Im viscerally aware of whats going on with my health.

Deep down, I know the cough is due to my allergies acting up, and my stomach is probably reacting to something I ate.

Since I was a child, my life has been all about maintaining my health and trying to get better, while doing my best to avoid getting worse.

I wish it were easier for me to tell people about the daily stressors that CF causes me, but my loved ones already worry enough about me in addition to handling issues in their own lives. I dont want to burden them by opening up about my thoughts about whats happening with my body as I get older.

Along with adopting a healthy lifestyle, I hope to participate in future clinical trials that may benefit people like me, the 10% of us who have rare, nonsense gene mutations and dont qualify for treatment with CFTR modulators. I want to be part of something that helps not only me, but also others like me. To participate in many of these studies, I must maintain a certain baseline of health, so I often obsessively monitor my weight and my cough.

I know that if excessive coughing one day extends to multiple days, it probably means I need an antibiotic to fight off a lung infection. But to participate in one of these studies, Im told I must be off antibiotics for a month ahead of time. It can be a fine line between coughing from allergies and from a lung infection, so I must ensure that Im reacting properly to the situation without letting anxiety get the best of me.

At the end of the day, its about understanding that a few extra coughs or a gassier stomach may be temporary. Its not the end of the world, and Ill be OK. I must take life on one day at a time and remember that todays issues doesnt guarantee that tomorrows will be the same.

Note:Cystic Fibrosis News Todayis strictly a news and information website about the disease. It does not provide medical advice,diagnosis, ortreatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofCystic Fibrosis News Todayor its parent company, BioNews, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read more:

Controlling anxiety is a key part of managing my health with CF - Cystic Fibrosis News Today

This paediatric-focused study evaluates annual changes in the incidence and prevalence rates of respiratory pathogens across different age groups, while also comparing medication prescription trends over an 18-year period. This study provides valuable data from a real-world clinical setting where infants under the age of one receive universal antimicrobial prophylaxis and, standardised respiratory pathogen surveillance is conducted by qualified personals using consistent sampling and microbiological testing protocols. In particular, obtaining samples through sputum and oropharyngeal suctioning is considered to have the highest concordance with BAL samples, rendering them more representative of lower airway infections compared to other sampling methods like throat or cough swabs18. The findings contribute to our understanding of the long-term trends in respiratory pathogens and associated clinical management in the paediatric population, particularly in the modern era of eradication therapy15.

Our study showed that together, S. aureus and P. aeruginosa make up the majority of respiratory pathogens both in terms of incidence (51.3%) and prevalence (82.3%). Data preceding 2000, report prevalence of these two respiratory pathogens to be higher at 95%14.

Registry data taken from 2018 to 2020 showed a prevalence of P. aeruginosa of 20.9%17 and S. aureus of 55.26% in children and adolescents under the age of 18. In comparison, our data shows a recent prevalence of P. aeruginosa of 17.6% and S. aureus of 45.3%. Of the less frequent respiratory pathogens, NTM prevalence was 4.3% from registry data vs 3.7% from our cohort and B.cepaciawas 3.2% vs. 1.3% respectively.

In a recent publication by VanDevanter et al., a trend of decline in P. aeruginosa prevalence was observed, as evidenced by the examination and presentation of registry data within a comparable time frame19. Following this, Fischer et al. raised a crucial question regarding whether the observed changes in P. aeruginosa over time were also apparent in other respiratory pathogens of interest in CF20. We have demonstrated that over the past 18years, the incidence and prevalence of the most common respiratory pathogens in CF such as S. aureus, P. aeruginosa, H. influenzae and A. fumigatus have decreased steadily. This significant decline of between 2 and 4% of individual respiratory pathogens are observed both in the incidence and prevalence. Meanwhile, less common organisms such as NTM, B. cepacia and A. xylosoxidans, S. maltophilia showed no significant change in terms of incidence and prevalence.

We also found that the incidence and prevalence of respiratory pathogens remain unchanged for infants up to 2years of age across all respiratory pathogens. Additionally, we have found that our cohort of children and adolescents with CF are found to have a positive airway sample culture for these respiratory pathogens significantly later that the earlier years of this study.

Our centre has adopted the universal use of S. aureus prophylactic antibiotics in infants diagnosed with CF preceding this study period. In a systematic analysis performed which reviewed four studies, there was a weak indication that P.aeruginosa was isolated less frequently in children under three years and more frequently in children between three to six years in the prophylactic group21. In contrast, despite our universal use of prophylactic antibiotics in infants, our study shows (1) a decline in the incidence and prevalence of P. aeruginosa, (2) no significantincrease in the incidence and prevalence of organisms such as NTM and B. cepacia (3) an increase in the mean age of first isolation of respiratory pathogens of interest, (4) no change of incidence and prevalence of respiratory pathogen<2years of age. A contributing factor in terms of improvements in infection control practices may have helped keep our incidence and prevalence lower than the national average. While being potentially circumstantial, these findings suggest that the use of prophylactic anti-staphylococcal antibiotics is not associated with an increase in P. aeruginosa or increase in prevalence of other less common respiratory pathogen. Prospective studies such as the CF-START study in evaluating outcomes of prophylactic treatments will hopefully provide conclusive proof of its benefits and safety21.

By examining prescription trends, we have found that there is a rise in the use of anti-pseudomonal nebulised antibiotics such as amikacin and colistin. This suggests that P.aeruginosa is being more aggressively treated over time as both this antibiotics are considered as second line after tobramycin22. However, the increase in use of amikacin could also be attributed to an increase in NTM incidence and prevalence. Encouragingly, we have found that the emphasis on respiratory clearance has increased over time with the significant increase in the prescription of dornase alpha and hypertonic saline in our cohort.

Our study comes with certain limitations that warrant consideration. Firstly, the sputum and prescription data lack representation from external laboratories or pharmacies, potentially limiting the comprehensiveness of our findings. Additionally, we did not culture anaerobic bacteria and did not routinely test for co-infection with respiratory viruses, leading to an omission in addressing potential co-infections among these organisms in our study. Moreover, the annual frequency of NTM testing, as opposed to routine CF airway sample cultures, may result in an underrepresentation of NTM within our study cohort.

Thirdly, our data originated from a single CF centre in Australia, raising concerns about the generalisability of our findings to a broader population. Fourthly, our incidence calculation may involve a small number of children or adolescents intermittently found to have these respiratory pathogens in their airway samples. Finally, the relatively limited sample size of children and adolescents on CFTR modulators or correctors is noteworthy, as our study predates the widespread adoption that followed the approval and government funding of these medications in Australia. Current evidence suggests that while it may more difficult to obtain sputum samples in children on CFTR therapy, its impact on the growth of specific bacterial pathogens needs to be closely examined23. The low number of children or adolescents on CFTR modulators or correctors is an important aspect of this study as it will enable future comparison in a post-modulator era in the management of CF.

Our study has several strengths. First, we analysed a large number of sputum samples, both overall and in different age groups, providing a longitudinal comparison of changes in CF treatment over the past 18years. This is the first study of such magnitude in children and adolescents with CF, providing age-specific incidence and prevalence, as well as prescription trends. In particular, our review of incidences of these organisms and the age of first positive culture provides additional information towards our understanding of CF respiratory pathogens over the past two decades.

Second, our study includes a large cohort of children born on or after January 1st, 2002, when newborn screening has already been well-established, allowing us to assess the acquisition of respiratory pathogens from shortly after birth over the past 18years. Third, the practice of using prophylactic anti-staphylococcus antibiotics universally has given us the opportunity to assess the outcomes of its use over a significantly long period of time. While strong conclusions cannot be made without a non-prophylactic control arm, it does provide insight into the long-term impact of its implementation on respiratory pathogens in our cohort.

In summary, our study shows a change in the epidemiology of CF pathogens in a single large paediatric clinic that practices universal prophylaxis in children. First, we observed a decline in the incidence and prevalence of the most commonly found CF pathogens such as S. aureus, P. aeruginosa, H. influenzae, and A. fumigatus, as well as a delay in the first acquisition of these pathogens. However, less common pathogens such as S. marcescens, NTM, B. cepacia, A. xylosoxidans, and S. maltophilia did not show significant changes. Second, we found no change in the incidence or prevalence of respiratory pathogens in infants under 2years of age over time.

Read the rest here:

The changing epidemiology of pulmonary infection in children and adolescents with cystic fibrosis: an 18-year ... - Nature.com

April 20, 2024, 08:44 am ET, BY Mitchell H.- Contributor| Editor: Thomas H. Kee Jr. (Follow on LinkedIn)

The technical summary data tells us to buy CF near 76.95 with an upside target of 83.36. This data also tells us to set a stop loss @ 76.73 to protect against excessive loss in case the stock begins to move against the trade. 76.95 is the first level of support below 79.47 , and by rule, any test of support is a buy signal. In this case, support 76.95 would be being tested, so a buy signal would exist.

The technical summary data is suggesting a short of CF as it gets near 83.36 with a downside target of 76.95. We should have a stop loss in place at 83.6though. 83.36 is the first level of resistance above 79.47, and by rule, any test of resistance is a short signal. In this case, if resistance 83.36 is being tested, so a short signal would exist.

If 83.36 begins to break higher, the technical summary data tells us to buy CF just slightly over 83.36, with an upside target of 89.83. The data also tells us to set a stop loss @ 83.12 in case the stock turns against the trade. 83.36 is the first level of resistance above 79.47, and by rule, any break above resistance is a buy signal. In this case, 83.36, initial resistance, would be breaking higher, so a buy signal would exist. Because this plan is based on a break of resistance, it is referred to as a Long Resistance Plan.

The technical summary data is suggesting a short of CF if it tests 83.36 with a downside target of 79.11. We should have a stop loss in place at 83.6 though in case the stock begins to move against the trade. By rule, any test of resistance is a short signal. In this case, if resistance, 83.36, is being tested a short signal would exist. Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan.

If 79.95 begins to break higher, the technical summary data tells us to buy CF just slightly over 79.95, with an upside target of 83.36. The data also tells us to set a stop loss @ 79.76 in case the stock turns against the trade. 79.95 is the first level of resistance above 79.47, and by rule, any break above resistance is a buy signal. In this case, 79.95, initial resistance, would be breaking higher, so a buy signal would exist. Because this plan is based on a break of resistance, it is referred to as a Long Resistance Plan.

The technical summary data is suggesting a short of CF if it tests 79.95 with a downside target of 79.11. We should have a stop loss in place at 80.14 though in case the stock begins to move against the trade. By rule, any test of resistance is a short signal. In this case, if resistance, 79.95, is being tested a short signal would exist. Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan.

Real Time Updates are available on our Cf Industries Holdings Inc. (CF) Page here: CF.

CF Ratings for April 20:

Blue = Current Price Red= Resistance Green = Support

Click the Get Real Time Updates button below.

In the login prompt, select forgot username

Type the email you use for Factset

Use the user/pass you receive to login

You will have 24/7 access to real time updates.

From then on you can just click to get the real time update whenever you want.

GET REAL TIME UPDATES

Evitar Corte warned of market crash risk four times since 2000.

It identified the Internet Debacle before it happened.

It identified the Credit Crisis before it happened.

It identified the Corona Crash too.

See what Evitar Corte is Saying Now.

Get Notified When our Ratings Change:Take a Trial

When#institutionalinvestors make decisions to buy and sell #stocks they normally want to keep it quiet. However, if we pay close attention we can see what is going on, and make good decisions.. The Cf Industries Holdings Inc.(NYSE: CF) report below can help you understand how to do this. The trading plans for CF, are updated in real time for subscribers, but this report is static. If you want an update, or a different report on a different stock, please get one here Unlimited Real Time Reports.

Fundamental Charts for CF:

Visit link:

Learn to Evaluate (CF) using the Charts - Stock Traders Daily

Orlando City got back to winning ways last Saturday and started a mini-undefeated streak in the process, as the Lions have now gone three games on the bounce without tasting defeat. OCSC has two more games to play during the month of April, and the scheduling gods have given the men in purple a chance to keep building on the recent run of good form, as a tricky and packed May schedule looms on the horizon. The last two April fixtures wont be easy by any stretch, but an opportunity has presented itself if the Lions can play well and take advantage of it.

First, lets turn our attention to Saturdays game against CF Montreal up in Canada. Montreal currently has a record of 3-3-1 which is good for 10 points and eighth place in the Eastern Conference. These two teams faced each other in the very first game of the season, and it ended as a 0-0 draw, thanks largely in part to some shaky finishing on Orlandos part and a couple excellent Pedro Gallese saves. Since then, Montreal has defeated a struggling FC Dallas team, an Inter Miami team that has looked equal parts unbeatable and extremely vulnerable at the back, and an FC Cincinnati side that so far has struggled to replace the goals of Brandon Vazquez. In other words, the wins havent come over bad teams, (aside from maybe Dallas) but rather teams that have had flawed, uneven starts to the season.

To be fair, many of the same criticisms could be leveled at Orlando Citys record. OCSCs wins have come against Austin FC and D.C. United two teams with leaky defenses that have each had uneven starts to the season and the Lions have suffered losses that have ranged from uninspiring against Atlanta, to abhorrent against Miami. Where the two teams differ is that Orlando started the year battling on two fronts and then had key players missing through a combination of injury and international call-ups afterward. The Lions now have a nearly clean bill of health and looked much more cohesive with Wilder Cartagena and Cesar Araujo partnered in midfield once more a welcome sight after some of the struggles that were endured when one or both were missing at various times.

The Canadian side also hasnt kept a clean sheet since that opening game of the season against the Lions, a fact that could bode well for an Orlando side which has scored six goals in its last three games. As long as the defense can tighten up and not make the sorts of mental errors that led to goals against D.C. and the New York Red Bulls, there will be opportunities at the other end of the field for an attacking corps that has done a better job at putting the ball in the net than we saw during the first game of the season. In short, the game is a winnable one, and while getting road results in MLS is never easy, OCSC should feel reasonably confident about its chances to get points on its trip north of the border.

That leaves Toronto FCs visit to the Purple Palace on Saturday, April 27. The Reds currently sit one spot below CF Montreal, in ninth place, with a record of 3-4-1 and 10 points. TFCs victories have been over a New England team that has been struggling mightily, a Charlotte FC side that has had a decent but slightly inconsistent start to the year, and an Atlanta United outfit that can have the same said of it as Charlotte. The wins have all been solid ones, and the team looked pretty good in those three games.

On the flip side of things, the last of those wins came on March 23, with Toronto dropping its last three games in a row and conceding 10 goals in the process. Theyve got the second leakiest defense of any of the nine teams in the playoff places, while being tied with Cincinnati for scoring the fewest goals.

Then theres the issue of player availability. The Reds injury list is a long one, with six players currently listed as out and an additional one as questionable. Among those listed out are Lorenzo Insigne, Richie Laryea, Brandon Servania, and Shane ONeill. In other words, theyre likely to be missing guys that are key contributors for the team when healthy, and part of the recent losing streak can be attributed to dealing with the injury bug thats bit the team with a vengeance. Playing on the road without a number of important key players is rarely a recipe for success, and Orlando City should have another good chance to pick up three points.

Now, this isnt to say that taking all six points from these games is a foregone conclusion. MLS is a tricky league to get results in, and we have no way of knowing how the fortunes of Orlando, Montreal, and Toronto will change in the next eight days. But given the leaky defenses of the two Canadian sides, TFCs injury situation, and Orlando City seemingly starting to find a better patch of form, the Lions have an opportunity to keep picking up points and climbing the Eastern Conference standings. Vamos Orlando!

Read the original:

Orlando City at CF Montreal: Three Keys to Victory - The Mane Land

Associated Press

Orlando City SC (2-3-2, 12th in the Eastern Conference) vs. CF Montreal (3-3-1, eighth in the Eastern Conference)

Montreal, Quebec; Saturday, 7:30 p.m. EDT

BETMGM SPORTSBOOK: LINE Montreal +154, Orlando City SC +159, Draw +237; over/under is 2.5 goals

BOTTOM LINE: CF Montreal faces Orlando City in Eastern Conference play.

Montreal is 2-2-1 against Eastern Conference opponents. Matias Coccaro paces the seventh-ranked scoring team in the Eastern Conference with three. Montreal has scored 10 goals.

Orlando is 1-2-2 against Eastern Conference opponents. Orlando ranks 10th in the Eastern Conference giving up just 13 goals.

Saturday's game is the second time these teams square off this season. The last meeting ended tied 0-0.

TOP PERFORMERS: Coccaro has scored three goals with one assist for Montreal. Josef Martinez has two goals and three assists.

Duncan McGuire has three goals for Orlando. Dagur Dan Thorhallsson has one goal and one assist.

SEASON SO FAR: Montreal: Averaging 1.4 goals, 3.9 shots on goal and 3.6 corner kicks through seven games while allowing 2.0 goals per game.

Orlando: Averaging 1.1 goals, 4.0 shots on goal and 6.7 corner kicks through seven games while allowing 1.9 goals per game.

NOT EXPECTED TO PLAY: Montreal: Jules-Anthony Vilsaint (injured), Nathan-Dylan Saliba (injured), Kwadwo Opoku (injured), Dominik Yankov (injured).

Orlando: Ramiro Enrique (injured).

___

The Associated Press created this story using technology provided by Data Skrive and data from Sportradar.

The rest is here:

CF Montreal plays Orlando City in conference action - FOX Sports

Valencia CF goalkeeper Giorgi Mamardashvili continues to rack up milestones in his career. The Tbilisi native is the goalkeeper who has saved the most penalties (3) in this LALIGA EA Sports 23-24 season.

Throughout the history of Valencia CF in the Spanish top flight, he has been awarded 423 penalties against him, of which 284 have been goals (67%), 93 have been saved and 46 have been missed. These figures are highlighted by the fact that Valencia CF's goalkeepers are the ones who have saved the most penalties in the history of the Spanish top-flight.

Mamardashvili has once again reached a milestone in his career. He is currently the goalkeeper who has saved the most penalties (3) in the 31 games played in LALIGA EA Sports 23-24.

This great performance between the posts in spot-kicks from twelve yards out and his great performances in these fixtures have made Valencia CF the third lowest-scoring team in the domestic competition with 32 goals. This figure is reinforced by the 12 clean sheets (9 at Mestalla and 3 away) he has kept so far.

Throughout this process, it is worth noting that the Valencianista goalkeeper has become the goalkeeper with the most consecutive starts in the LALIGA (69) and has beaten his personal best for the most clean sheets (12) in the competition.

Visit link:

Mamardashvili boast the highest spot-kick saves this season - Valencia CF

Valencia CF goalkeeper, Jaume Domnech, speaks to VCF Media after signing his contract extension with Valencia CF.

The team's surprise

"I didn't expect it, it was actually a very pleasant surprise. Seeing Georgi and Jos here with me and saying that about me made me very happy. Happy for the renewal and happy to listen to my teammates and what they think of me. That gives me even more strength to continue training hard every day, to continue helping the team, the club, to continue meeting objectives and to continue growing".

Saturday's game against Real Betis

Yes, this Saturday is going to be an exciting game. We are very excited, and we are training in a very, very focused way. Mestalla has been accompanying us all year in a spectacular way and this Saturday is going to be the same. With our fans and playing at home, I believe that we are going to be able to achieve the win and continue growing - and see how far we can go.

The dressing room

Yes, we have a very united group, but it is also true that it is still a very, very young group, without a lot of experience. In everyday moments, in preseason, during the season, when I see opportune moments, I try to talk to each one of them, anticipating what I think could happen, preventing those situations that could occur, and I think that that's important too. And they value it because it's like getting them aware of a situation before something happens. I feel comfortable helping them and that is why some of them will tell you that I am like a father to them.

Valencia CF career

I came up from the reserve team and I have the Valencia CF DNA within me. I have also been in the first team for many years, as captain too, with Jos, and in the end, we carry that within us. So I think we are the right people in the dressing room to transmit that to our teammates, to the younger ones, and also to the not-so-young ones who maybe come from somewhere else. I think we are achieving this, because everyone has a total commitment to the team, to the city, and to the club, and I think it is being seen day by day. We have to continue in this way to see how far we can grow.

Rubn Baraja

The absolute leader of the team is the coach, he is our example. He was a great player and that also leads you to have admiration before even meeting him. With what he is demonstrating as a coach, he has us all motivated, all prepared to play, or prepared not to play but to help from the outside. I think we are seeing total commitment and a very united team, and that is the key to our performance so far. We have to stay up there and continue along that path, even in the aspects that can be improved, improving them little by little.

The fanbase

The fans are incredible. We are really happy with them. Mestalla is packed for every game, they give us a lift and we have proof of that the other day in Pamplona. The fans travelled there and they gave us amazing support.

Visit link:

Jaume Domnech: "I have the VCF DNA inside me" - Valencia CF

"Lionel Messi is the GOAT of the assist," said Jen Wilson, Lowe's senior vice president of enterprise brand and marketing. "Partnering with him is the perfect reflection of Lowe's shared passion for assisting our customers, whether for their business or home."

To kick off his first season, Lowe's and Messi will "assist" Lowe's loyalty customers with extra perks. Starting today, all loyalty members will receive 100 points to get them closer to their next reward through Lowe's new loyalty program for homeowners,MyLowe's Rewards, and Lowe'sMVPs Pro Rewards for Pros. MyLowe's Rewards members must claim points on their account dashboard by May 18.*

"Ftbol, much like home improvement, is all about teamwork and the assistance between people," Messi said. "I am happy to partner with Lowe's, a brand that understands the importance of collaboration and helping people succeed."

Inter Miami has quickly become the focal point of soccer in North America. The new partnership between Lowe's and Inter Miami will drive engagement with soccer fans with signage and in-stadium activations, community programming, ticket hospitality, player appearances at Lowe's locations throughout the Miami market and more.

"Inter Miami has worked towards becoming a global reference point of ftbol, so that when people think of ftbol, they think of Inter Miami," said Inter Miami CF Chief Business Officer, Xavier Asensi. "Our partnership with Lowe's is another proof point of attaining this ambition. We are excited to partner with Lowe's, an organization that matches our goal to continue to set the benchmark for the sport and deliver for our ftbol family."

Lowe's will also team up with CONMEBOL Copa Amrica2024 USA, which returns to the United States with Argentina defending its crown beginning June 20. Lowe's has a series of exciting initiatives to celebrate the magic of Messi:

"To celebrate ftbol's rich culture and community, we wanted to partner with an athlete and ftbol affiliations that resonate deeply with our customers," said Gerardo Soto, Lowe's vice president of brand marketing and sports partnerships. "These new partnerships provide an opportunity to build trust and credibility with a broader customer base through the athletes and sporting events that matter to them."

The partnerships add to Lowe's existing collaboration with Charlotte FC, Lowe's hometown Major League Soccer club. As the Official Home Improvement Partner of Inter Miami CF and CONMEBOL Copa Amrica2024 USA, Lowe's will enhance the soccer experience for fans while bringing them closer to the excitement of Messi's gameplay.

For more information about Lowe's partnerships and upcoming soccer initiatives, visitLowes.com/hometeam.

* Loyalty Programs subject to Terms & Conditions. Visit Lowes.com/Terms for details. Subject to change.

**All Bonus Points will expire on December 31, 2024, unless extended by Lowe's. Reward Center items may vary. Visit Lowes.com/terms for full details.

About Lowe's Lowe's Companies, Inc. (NYSE: LOW) is a FORTUNE 50 home improvement company serving approximately 16 million customer transactions a week in the United States. With total fiscal year 2023 sales of more than $86 billion, Lowe's operates over 1,700 home improvement stores and employs approximately 300,000 associates. Based in Mooresville, N.C., Lowe's supports the communities it serves through programs focused on creating safe, affordable housing and helping to develop the next generation of skilled trade experts. For more information, visit Lowes.com.

About Inter Miami CF Club International de Ftbol Miami, known as Inter Miami CF, is an American professional sports team in its fifth season in Major League Soccer. Inter Miami plays and trains at its 34-acre centralized facility, which includes the 21,500-capacity Chase Stadium, a 50,000-square-foot training center and seven fields in Fort Lauderdale, Florida. In addition to the MLS team, the Club fields MLS NEXT Pro team Inter Miami CF II and has a youth Academy for ages U-12 to U-19. Inter Miami CF Main Partners include: Royal Caribbean, JPMorgan Chase, Fracht Group, Baptist Health and Florida Blue. Please visitwww.intermiamicf.com for more information.

About CONMEBOL Copa Amrica 2024 USA

The CONMEBOL Copa Amrica 2024 USA will be played in the United States and will include 10 CONMEBOL teams and 6 guest teams from Concacaf. In this edition, this traditional tournament is organized by both confederations. In its 48th edition of one of the continent's most important competitions, this will be the second time in the tournament's history that it will host 16 teams, having hosted the same number of teams in its 2016 edition, also held in the United States. On the field will be the current world champion, Argentina, and the biggest football stars in the world to compete in 32 matches in this edition between June and July 2024.

Contact:

Steve Salazar Lowe's Companies, Inc. [emailprotected]

SOURCE Lowe's Companies, Inc.

Read more from the original source:

Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Soccer ... - PR Newswire